CL King Begins Coverage on Repligen (RGEN)

Equities researchers at CL King initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Monday, November 13th, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. CL King’s price objective indicates a potential upside of 15.46% from the company’s previous close.

Several other research analysts have also recently weighed in on RGEN. William Blair began coverage on shares of Repligen in a report on Friday, July 21st. They set an “outperform” rating for the company. BidaskClub cut shares of Repligen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Saturday, August 12th. TheStreet upgraded shares of Repligen from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Finally, Jefferies Group reiterated a “hold” rating and set a $40.00 price objective on shares of Repligen in a research report on Thursday, September 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Repligen presently has a consensus rating of “Buy” and a consensus target price of $44.67.

Repligen (NASDAQ RGEN) opened at $35.51 on Monday. Repligen has a 52 week low of $28.48 and a 52 week high of $46.81. The stock has a market cap of $1,550.00, a P/E ratio of 61.12, a PEG ratio of 2.31 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same period in the previous year, the company earned $0.08 earnings per share. The firm’s quarterly revenue was up 48.2% on a year-over-year basis. equities analysts expect that Repligen will post 0.61 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Repligen by 3.7% in the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after acquiring an additional 170,551 shares during the period. TimesSquare Capital Management LLC raised its stake in shares of Repligen by 19.8% in the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after acquiring an additional 390,545 shares during the period. Vanguard Group Inc. raised its stake in shares of Repligen by 9.7% in the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after acquiring an additional 175,191 shares during the period. Conestoga Capital Advisors LLC increased its stake in Repligen by 12.5% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock worth $55,688,000 after buying an additional 161,427 shares during the period. Finally, FMR LLC increased its stake in Repligen by 6.2% in the 2nd quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock worth $55,285,000 after buying an additional 78,060 shares during the period. 83.18% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “CL King Begins Coverage on Repligen (RGEN)” was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/repligen-corporation-rgen-earns-buy-rating-from-analysts-at-cl-king/1781784.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.